Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2.

Investigative ophthalmology & visual science - 1 Jul 2024

Guymer Robyn H, Silva Rufino, Ghadessi Mercedeh, Leal Sergio, Gashaw Isabella, Damask Amy, Paulding Charles, Rittenhouse Kay D

Abstract excerpt

Purpose: This analysis investigated potential associations between gene variants and clinical end points in the VIEW 1 and 2 randomized clinical trials of intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD). Methods: A genome-wide association analysis was conducted in a subgroup of patients from VIEW 1 and 2 consenting to the optional pharmacogenetic analysis. Results:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Anoctamins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Intravitreal Injections

Share to Pharmacogenomic Testing

Share to Receptors, Vascular Endothelial Growth Factor

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Open in PubMed Open full text

Identifiers

PMID: 38980270
DOI: 10.1167/iovs.65.8.17
PMCID: PMC11244643

Genes

ANO2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2.PMID 38980270Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Clinical and Genetic Spectrum of ACO2-Linked Dominant Optic Atrophy.Semantic proximity Read ↗

Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Semantic proximity Read ↗

Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Relationship between Aflibercept Efficacy and Genetic Variants of Genes Associated with Neovascular Age-Related Macular Degeneration: The BIOIMAGE Trial.Semantic proximity Read ↗

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.